相似文献
1
Multiple Myeloma: Diagnosis and Treatment.
Mayo Clin Proc. 2016 Jan;91(1):101-19. doi: 10.1016/j.mayocp.2015.11.007.
2
Myeloma today: Disease definitions and treatment advances.
Am J Hematol. 2016 Jan;91(1):90-100. doi: 10.1002/ajh.24236.
3
The effect of novel therapies in high-molecular-risk multiple myeloma.
Clin Adv Hematol Oncol. 2017 Nov;15(11):870-879.
4
How is patient care for multiple myeloma advancing?
Expert Rev Hematol. 2017 Jun;10(6):551-561. doi: 10.1080/17474086.2017.1326814. Epub 2017 May 19.
5
Emerging therapies in multiple myeloma.
Am J Clin Oncol. 2015 Jun;38(3):315-21. doi: 10.1097/COC.0b013e3182a4676b.
6
[Current treatment of refractory and relapsed multiple myeloma].
Rinsho Ketsueki. 2016;57(10):2084-2095. doi: 10.11406/rinketsu.57.2084.
7
Meeting report of the 6th Heidelberg Myeloma Workshop: current status and developments in diagnosis and therapy of multiple myeloma.
J Cancer Res Clin Oncol. 2017 Dec;143(12):2521-2526. doi: 10.1007/s00432-017-2463-x. Epub 2017 Jun 26.
8
Safety issues and management of toxicities associated with new treatments for multiple myeloma.
Expert Rev Hematol. 2017 Mar;10(3):193-205. doi: 10.1080/17474086.2017.1284584. Epub 2017 Jan 27.
9
Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
Clin Lymphoma Myeloma Leuk. 2022 Jul;22(7):460-473. doi: 10.1016/j.clml.2022.01.011. Epub 2022 Jan 19.
10
Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
J Oncol Pharm Pract. 2016 Apr;22(2):289-302. doi: 10.1177/1078155215572036. Epub 2015 Feb 17.
引用本文的文献
1
Impact of type 2 and steroid-Induced diabetes mellitus on prognosis in patients with multiple myeloma.
World J Surg Oncol. 2025 Aug 30;23(1):330. doi: 10.1186/s12957-025-03982-0.
2
Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.
Int J Hematol Oncol Stem Cell Res. 2025 Apr 1;19(2):180-190. doi: 10.18502/ijhoscr.v19i2.18555.
3
Polymorphisms in Necroptosis Pathway Genes: Novel Prognostic Markers for Multiple Myeloma Treatment Outcomes.
Int J Mol Sci. 2025 May 29;26(11):5237. doi: 10.3390/ijms26115237.
4
An Updated Indirect Comparison of Elranatamab Versus a Real-World External Control Arm in Triple-Class Refractory Multiple Myeloma.
Blood Lymphat Cancer. 2025 Jun 5;15:11-20. doi: 10.2147/BLCTT.S516356. eCollection 2025.
5
MAMDC2-AS1 Induces Cuproptosis in Relapsed and Refractory Multiple Myeloma.
Cancer Rep (Hoboken). 2025 May;8(5):e70216. doi: 10.1002/cnr2.70216.
6
Efficacy of maintenance or consolidation therapy for multiple myeloma based on proteasome inhibitors: a meta-analysis.
Discov Oncol. 2025 Apr 12;16(1):519. doi: 10.1007/s12672-025-02304-w.
7
Daratumumab, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Meta-Analysis.
Hematol Oncol. 2025 May;43(3):e70061. doi: 10.1002/hon.70061.
8
A Randomized Controlled 'REAL-FITNESS' Trial to Evaluate Physical Activity in Patients With Newly Diagnosed Multiple Myeloma.
J Cachexia Sarcopenia Muscle. 2025 Apr;16(2):e13793. doi: 10.1002/jcsm.13793.
9
Challenges in Multiple Myeloma Therapy in Older and Frail Patients.
Cancers (Basel). 2025 Mar 11;17(6):944. doi: 10.3390/cancers17060944.
10
Genetic evidence identifies a causal relationship between EBV infection and multiple myeloma risk.
Sci Rep. 2025 Feb 21;15(1):6357. doi: 10.1038/s41598-025-90479-1.
本文引用的文献
1
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Blood Cancer J. 2020 May 11;10(5):53. doi: 10.1038/s41408-020-0311-8.
2
Interpretation of cytogenetic results in multiple myeloma for clinical practice.
Blood Cancer J. 2015 Oct 30;5(10):e365. doi: 10.1038/bcj.2015.92.
3
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
4
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
N Engl J Med. 2015 Aug 13;373(7):621-31. doi: 10.1056/NEJMoa1505654. Epub 2015 Jun 2.
5
Smoldering multiple myeloma.
Blood. 2015 May 14;125(20):3069-75. doi: 10.1182/blood-2014-09-568899. Epub 2015 Apr 2.
6
Improvement in renal function and its impact on survival in patients with newly diagnosed multiple myeloma.
Blood Cancer J. 2015 Mar 20;5(3):e296. doi: 10.1038/bcj.2015.20.
7
Clinical Course and Prognosis of Non-Secretory Multiple Myeloma.
Eur J Haematol. 2015 Feb 16. doi: 10.1111/ejh.12534.
8
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
Blood. 2015 Mar 26;125(13):2068-74. doi: 10.1182/blood-2014-12-615187. Epub 2015 Jan 27.
9
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
10
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Lancet Oncol. 2014 Nov;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5. Epub 2014 Oct 26.
Zotero 插件